-
ESMO Global Insight | Professor Andrea Necchi: Disitamab Vedotin Plus Immunotherapy Nearly Doubles Overall Survival in Advanced HER2-Expressing Urothelial Carcinoma
The combination of antibody–drug conjugates (ADCs) with immunotherapy has delivered major breakthroughs across several tumor types, including urothelial carcinoma. At the 2025 European Society for Medical Oncology (ESMO) Congress, results from a pivotal Phase III trial (LBA7) were presented showing that the HER2-targeted ADC disitamab vedotin, combined with the PD-1 inhibitor toripalimab, nearly doubled overall…
-
Highlights from the 13th International Conference of the Federation of Asian Clinical Oncology (FACO 2025)
At the recent FACO 2025 Conference held in Shanghai, Dr. Joon Oh Park, President of KSMO and President-elect of FACO, shared his perspectives on the evolving landscape of cancer treatment…
-
ESMO China Voice | Professor Jiesong Wang: The iPET-NCCN-IPI Model May Optimize Risk Stratification in Diffuse Large B-Cell Lymphoma
1243MO: Integrating Interim 18F-FDG PET-CT Analysis and NCCN-IPI for Risk Stratification in Diffuse Large B-Cell Lymphoma — A Multicenter Retrospective Study Q1 This study integrates interim National Comprehensive Cancer Network…
-
ESMO China Voice | Dr. Sicong Zhang: Refractory DLBCL Patients Share Similar Immune Signatures
The European Society for Medical Oncology (ESMO) Congress 2025 was grandly held in Berlin, marking another wave of scientific innovation across the field of oncology.In hematology, several exciting advances drew attention—from uncovering the mechanisms of CAR-T resistance and exploring dual-target immunotherapies, to studies on precision treatment discontinuation in multiple myeloma and single-cell immune atlas mapping…
-
ESMO China Voice | Dr. Cong Sun: Grade 3B Follicular Lymphoma Is an Independent Risk Factor Affecting Both PFS and OS
To better focus on these hematologic breakthroughs and facilitate academic exchange, Oncology Frontier – Hematology News invited Dr. Cong Sun, from the research team of Professor Huilai Zhang at Tianjin…
-
ESMO China Voice | Prof. Liang Wang: CD19/CD22 Bispecific CAR-T Therapy Demonstrates Remarkable Efficacy and Safety in R/R LBCL
In hematology, this year’s highlights encompassed several cutting-edge research directions—from unraveling the mechanisms of CAR-T resistance and exploring dual-target immunotherapies that may enhance precision and efficacy, to studies on treatment-free remission in multiple myeloma, and the creation of single-cell immune atlases offering novel insights into hematologic disease mechanisms. These achievements collectively reflect the continued progress…
-
13th FACO Annual Academic Conference Grandly Held in Shanghai! Leading Experts from China, Japan, and South Korea Gather to Foster Clinical Oncology
Editor’s Note: Promoting collaboration through exchange, and seeking mutual success through cooperation — on October 24, 2025, the 13th Federation of Asian Clinical Oncology (FACO) Annual Conference was grandly held…
-
Professor Li Jin: Asian Clinical Oncology Experts Converge at FACO Conference to Jointly Promote Regional Collaboration and Advance the Level of Diagnosis and Treatment for Common Asian Cancers
The 13th International Conference of the Federation of Asian Clinical Oncology (FACO 2025) will be grandly held in Shanghai from October 24 to 25, 2025. The conference is jointly organized by the Federation of Asian Clinical Oncology (FACO), the Chinese Society of Clinical Oncology (CSCO), the Beijing CSCO Clinical Oncology Research Foundation, and the Eastern…
Connecting Medical Expertise through Media